Price
Financials
Consolidated, Rs crore| Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 339 | 525 | 498 | 483 | 540 | 550 | 423 | 611 | 418 |
| Expenses | 218 | 330 | 338 | 288 | 349 | 332 | 266 | 344 | 268 |
| Operating Profit | 121 | 195 | 160 | 195 | 191 | 218 | 157 | 267 | 151 |
| OPM % | 36% | 37% | 32% | 40% | 35% | 40% | 37% | 44% | 36% |
| Other Income | 19 | 28 | 24 | 14 | 23 | 48 | 8 | 52 | 25 |
| Interest | 4 | 4 | 3 | 1 | 2 | 3 | 0 | 2 | 1 |
| Depreciation | 19 | 20 | 20 | 30 | 26 | 34 | 35 | 40 | 30 |
| Profit before tax | 118 | 200 | 161 | 178 | 186 | 230 | 130 | 278 | 145 |
| Tax % | 30% | 19% | 23% | 54% | 27% | 24% | 29% | 32% | 17% |
| Net Profit | 82 | 162 | 124 | 83 | 136 | 173 | 93 | 190 | 120 |
| EPS in Rs | 1.47 | 2.90 | 2.22 | 1.48 | 2.42 | 3.09 | 1.65 | 3.38 | 2.13 |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|
| Sales | 633 | 1,103 | 1,231 | 1,057 | 1,419 | 1,845 | 2,124 | 2,002 |
| Expenses | 451 | 695 | 666 | 626 | 914 | 1,173 | 1,290 | 1,209 |
| Operating Profit | 182 | 408 | 565 | 431 | 506 | 672 | 834 | 793 |
| OPM % | 29% | 37% | 46% | 41% | 36% | 36% | 39% | 40% |
| Other Income | 21 | 37 | 49 | 139 | 63 | 85 | 131 | 133 |
| Interest | 20 | 17 | 10 | 9 | 10 | 11 | 7 | 6 |
| Depreciation | 62 | 62 | 58 | 64 | 82 | 89 | 134 | 138 |
| Profit before tax | 121 | 366 | 546 | 497 | 477 | 657 | 824 | 783 |
| Tax % | 23% | 26% | 26% | 23% | 23% | 31% | 28% | |
| Net Profit | 93 | 271 | 406 | 385 | 367 | 451 | 592 | 576 |
| EPS in Rs | 110.62 | 319.74 | 462.09 | 6.75 | 6.57 | 8.07 | 10.54 | 10.25 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 19% |
| 10 Years | 5 Years | 3 Years | TTM | 1 Year | Last Year | |
|---|---|---|---|---|---|---|
| Compounded Sales Growth | % | 14% | 26% | -2% | ||
| Compounded Profit Growth | % | 17% | 21% | 18% | ||
| Stock Price CAGR | % | % | % | 14% | ||
| Return on Equity | % | 23% | 21% | 22% |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Equity Capital | 8 | 8 | 9 | 114 | 112 | 112 | 112 |
| Reserves | 413 | 693 | 1,346 | 1,627 | 1,813 | 2,298 | 2,930 |
| Borrowings | 159 | 100 | 35 | 126 | 239 | 113 | 54 |
| Other Liabilities | 207 | 232 | 228 | 148 | 235 | 284 | 333 |
| Total Liabilities | 787 | 1,034 | 1,619 | 2,014 | 2,398 | 2,808 | 3,429 |
| Fixed Assets | 306 | 361 | 329 | 449 | 483 | 705 | 783 |
| CWIP | 50 | 19 | 154 | 164 | 345 | 297 | 264 |
| Investments | 99 | 209 | 273 | 499 | 472 | 433 | 1,007 |
| Other Assets | 333 | 445 | 863 | 902 | 1,099 | 1,373 | 1,374 |
| Total Assets | 787 | 1,034 | 1,619 | 2,014 | 2,398 | 2,808 | 3,429 |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Cash from Operating Activity | 166 | 278 | 333 | 306 | 140 | 271 | 844 |
| Cash from Investing Activity | -109 | -196 | -205 | -376 | -221 | -147 | -702 |
| Cash from Financing Activity | -48 | -63 | 181 | 64 | -77 | -136 | -40 |
| Net Cash Flow | 9 | 18 | 308 | -6 | -158 | -12 | 103 |
| Free Cash Flow | 119 | 159 | 307 | 112 | -156 | 12 | 637 |
| CFO/OP | 116% | 85% | 81% | 98% | 51% | 64% | 126% |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Debtor Days | 61 | 84 | 97 | 95 | 126 | 89 | 101 |
| Inventory Days | 186 | 29 | 52 | 139 | 129 | 167 | 56 |
| Days Payable | 87 | 50 | 50 | 77 | 61 | 54 | 34 |
| Cash Conversion Cycle | 160 | 63 | 99 | 156 | 193 | 202 | 124 |
| Working Capital Days | 20 | 27 | 75 | 112 | 128 | 134 | 92 |
| ROCE % | 55% | 51% | 28% | 24% | 28% | 30% |
| Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|
| Promoters | 74.69% | 74.69% | 74.67% | 71.42% |
| FIIs | 1.66% | 1.37% | 1.28% | 2.57% |
| DIIs | 7.21% | 7.60% | 11.55% | 13.48% |
| Public | 16.42% | 16.34% | 12.48% | 12.52% |
| No. of Shareholders | 2,17,681 | 1,99,492 | 1,80,220 | 1,73,273 |
Fundamentals
Market Cap₹ 48,996 Cr.
Current Price₹ 870
Stock P/E82.6
Book Value₹ 54.2
ROCE30.4 %
ROE22.3 %
Dividend Yield0.23 %
Face Value₹ 2.00
Compounded Sales Growth (TTM)-2%
Compounded Profit Growth (TTM)18%
Consolidated figures.
Valuation
Market capRs 48,819 Cr
Enterprise valueRs 48,603 Cr
P/E (TTM)82.49x
Price to book28.05x
Price to sales22.98x
EV / EBITDA50.36x
EV / EBIT58.48x
EV / sales22.88x
Price to cash flow159.55x
Earnings yield1.21%
Profitability
Operating margin (excl. other income)40.76%
Operating margin (incl. other income)53.90%
EBITDA margin45.44%
Pre-tax margin38.80%
Net profit margin27.86%
Net margin, latest quarter31.06%
ROE24.89%
ROCE31.07%
ROA21.20%
ROE, 3-year average37.54%
ROCE, 3-year average45.73%
ROA, 3-year average27.19%
ROIC (approx.)42.24%
Tax rate22.54%
Other income / net worth7.98%
Growth
Sales growth (latest year)-14.16%
Profit growth (latest year)-5.02%
Sales CAGR, 3 years18.65%
Profit CAGR, 3 years60.77%
Sales growth QoQ44.38%
Profit growth QoQ104.44%
Sales growth YoY (latest quarter)26.44%
Profit growth YoY (latest quarter)129.68%
Per share
EPS (TTM)Rs 10.37
EPS (latest year)Rs 6.75
EPS (latest quarter)Rs 3.33
EPS, 3-year averageRs 262.86
Book value per shareRs 30.51
Sales per shareRs 37.24
Cash flow per shareRs 5.36
Free cash flow per shareRs 11.17
Efficiency
Asset turnover0.52x
Fixed asset turnover2.35x
Inventory turnover3.09x
Inventory days118 days
Debtor days95 days
Debtors turnover3.86x
Creditor days34 days
Cash conversion cycle124 days
Working capital days92 days
Leverage
Total debtRs 126 Cr
Cash and bankRs 343 Cr
Net debtRs -217 Cr
Debt to equity0.07x
Net debt / EBITDA-0.22x
Interest coverage120.63x
Current ratio (filing 2026-03-31)5.54x
Quick ratio (filing 2026-03-31)5.15x
Trade payables (filing 2026-03-31)Rs 75 Cr
Owners' fund to total sources86.41%
Debt to assets6.26%
Cash flow
Cash from Operating Activity (latest year)Rs 306 Cr
Cash from Investing Activity (latest year)Rs -376 Cr
Cash from Financing Activity (latest year)Rs 64 Cr
Net Cash Flow (latest year)Rs -6 Cr
Free cash flow (latest year)Rs 637 Cr
FCFE (approx.: FCF + change in debt)Rs 728 Cr
Cash from ops / profit, 5 years0.86x
Sales to cash flow3.45x
Statement figures
Net sales (TTM)Rs 2,124 Cr
Net sales (latest year)Rs 1,057 Cr
Sales (latest quarter)Rs 611 Cr
Operating profit excl. other income (latest year)Rs 431 Cr
Operating profit (latest quarter)Rs 267 Cr
Other income (TTM)Rs 131 Cr
EBITDA (TTM)Rs 965 Cr
PBDT (TTM)Rs 958 Cr
Profit before tax (TTM)Rs 824 Cr
Tax (latest year)Rs 112 Cr
Net profit (TTM)Rs 592 Cr
Net profit (latest year)Rs 385 Cr
Net profit (latest quarter)Rs 190 Cr
Depreciation (TTM)Rs 134 Cr
Depreciation (latest quarter)Rs 40 Cr
Interest (TTM)Rs 7 Cr
Cost of goods sold (latest year)Rs 399 Cr
Total expenditure (latest year)Rs 626 Cr
Total income (latest year)Rs 1,196 Cr
Share capitalRs 114 Cr
ReservesRs 1,627 Cr
Shareholders' fundsRs 1,741 Cr
Total assetsRs 2,014 Cr
Net blockRs 449 Cr
Capital work in progressRs 164 Cr
InvestmentsRs 499 Cr
ReceivablesRs 274 Cr
InventoryRs 129 Cr
Other liabilitiesRs 148 Cr
Shares outstanding (crore)57.05
Ownership
Promoter holding71.42%
Computed by MarketFriction from the consolidated statements. Returns use average balances.
Not enough history to build valuation bands (needs two years of profits and prices).
| Period | ANTHEM | Nifty 50 | Difference |
|---|---|---|---|
| 1 week | -3.4% | -2.8% | -0.6 pts |
| 1 month | -7.4% | -6.8% | -0.6 pts |
| 3 months | +11.0% | -7.6% | +18.6 pts |
| 6 months | +30.4% | +0.4% | +30.0 pts |
| 1 year | +6.3% | -9.9% | +16.2 pts |
142 mutual fund schemes hold about ₹5,537 Cr.
Over three months 28 bought more and 39 sold (share counts, price move removed).
| Fund | Weight | Est. Cr | 3m shares |
|---|---|---|---|
| HDFC Flexi Cap Fund | 0.61% | 694 | -9% |
| SBI Midcap Fund | 1.57% | 386 | +3% |
| SBI Midcap Fund | 1.57% | 383 | +3% |
| Axis ELSS-Tax Saver Fund | 0.80% | 261 | +19% |
| Aditya Birla SL Flexi Cap Fund | 0.75% | 219 | -4% |
| SBI MNC Fund | 3.08% | 207 | -1% |
| UTI Mid Cap Fund | 1.40% | 179 | +58% |
| SBI Healthcare Opp Fund | 2.90% | 168 | -8% |
| Axis Midcap Fund | 0.47% | 161 | +18% |
| Kotak Multi Asset Allocation Fund | 0.92% | 141 | +15% |
| HDFC Business Cycle Fund | 4.30% | 119 | +2% |
| HDFC Pharma and Healthcare Fund | 3.48% | 115 | -18% |
| Nippon India Pharma Fund | 1.20% | 114 | +20% |
| Mahindra Manulife Mid Cap Fund | 2.10% | 114 | -2% |
| Mirae Asset Small Cap Fund | 1.94% | 111 | -12% |
| HDFC Manufacturing Fund | 1.04% | 110 | -16% |
| Axis Flexi Cap Fund | 0.77% | 107 | -0% |
| Axis Flexi Cap Fund | 0.77% | 104 | -0% |
| UTI Flexi Cap Fund | 0.40% | 96 | +54% |
| Axis Large & Mid Cap Fund | 0.55% | 95 | -1% |
| Axis Large & Mid Cap Fund | 0.55% | 93 | -1% |
| Mahindra Manulife Small Cap Fund | 1.63% | 89 | -6% |
| PGIM India Midcap Fund | 0.73% | 82 | +2% |
| Mahindra Manulife Multi Cap Fund | 0.89% | 69 | -6% |
| Canara Rob Large and Mid Cap Fund | 0.26% | 68 | +43% |
Red flags
F-score 2 of 8| explain | Share dilution Share count up 6383% in a year, 6692% in three |
| explain | Debt up, profit down Borrowings up 255% while net profit fell in 2026 |
| look | Inventory outrunning sales Inventory grew 122% vs sales -14% in 2026 |
| look | Auditor change Auditor change 2026-04-22: Anthem Biosciences Limited has informed the Exchange regarding Change in Auditors of the company. |
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.
Insider trades
NSE insider and takeover-code disclosures| Date | Who | Role | Side | Shares | Value | How |
|---|---|---|---|---|---|---|
| 2026-03-09 | Krithika Ganesh | Promoter Group | other | 8,557,302 | Gift | |
| 2026-03-09 | Aruna Ganesh | Promoter Group | other | 8,557,302 | Gift | |
| 2026-03-09 | Viridity Tone LLP | Other | sell | 20,313,795 | Rs 1255.25 Cr | Market Sale |
Latest disclosed trades by insiders, promoters and large holders. Grants, option exercises and pledges show as "other". A filing is a fact, not a signal on its own.
Latest quarter
Jun 2026Sales ₹418 Cr -22.6% vs Jun 2025.
Net profit ₹120 Cr -11.8%.
Against our estimate for Jun 2026: sales -26.8%, profit -25.3% miss. Our estimate for Sep 2026: sales Rs 561 Cr, profit Rs 168 Cr (how).
Activity
Compare| Company | Mcap (Cr) | P/E | ROCE |
|---|---|---|---|
| Advanced Enzyme Technologies Ltd | 3,152 | 20.0 | 14.0 % |
| CCME Global Ltd | 208 | -2.92 % | |
| Vivo Bio Tech Ltd | 36 | 7.74 % | |
| Shree Ganesh Biotech India Ltd | 19 | 1.31 % | |
| Genomic Valley Biotech Ltd | 9 | 886 | 1.02 % |
No bulk or block deals on record.
| Ex-date | Action | Factor |
|---|---|---|
| 2026-06-25 | Dividend - Rs 2 Per Share |
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
No short selling reported to NSE in our files.
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
Scrip PE is greater than 50 (4 trailing quarters)
Quick answers
What is the market cap of Anthem Biosciences Ltd?
Anthem Biosciences Ltd (ANTHEM) has a market capitalisation of Rs 48,996 Cr. at the 2026-10-01 close.
What is the P/E ratio of Anthem Biosciences Ltd?
Anthem Biosciences Ltd trades at a P/E of 82.6 on trailing twelve-month profit, at the 2026-10-01 close.
What were Anthem Biosciences Ltd's latest quarterly results?
In the Jun 2026 quarter, Anthem Biosciences Ltd sales was Rs 418 Cr (-22.6% vs Jun 2025) and net profit was Rs 120 Cr.
What is the 52-week high and low of Anthem Biosciences Ltd?
The 52-week high is Rs 977.55 and the 52-week low is Rs 579.15.